Our further analyses by comparing different classes of incretin-based agents suggested that GLP-1As were not associated with excess risks of either acute pancreatitis (OR = 0.75, 95% CI 0.47–1.17) or pancreatic cancer (OR = 0.94, 95% CI 0.49–1.83). This evidence concerns the gene GCG and pancreatic neoplasm.